China Reviews Broadcom Switch Use in State Data Centres 
Petrobras Joins Brazil Diesel Subsidy Program 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
U.S. Dollar Hits Eight-Week High After Fed Rate Hike 
Microsoft Stock Upgraded as Stifel Sees Stronger Azure Growth 
European Stocks Slip as Iran Tensions Offset Strong Eurozone Data 
US, Japan and South Korea Back Taiwan Ahead of Trump-Xi Summit 
US Stock Futures Rise as Meta Muse Fuels AI Rally 
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
Canada Unveils Bill to Fast-Track Major Resource Projects 
Asian Currencies Muted as Dollar Firms Ahead of Trump-Xi Summit 
Gold Drops Over 1% as Dollar, Treasury Yields Surge on Fed Rate Hike Bets 
Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
Yen Weakens as Dollar Gains on Widening US-Japan Rate Gap 
NASA, Boeing Discuss Expanding Starliner Missions 
Westinghouse Targets $50 Billion Valuation in U.S. IPO 
Add as a preferred source on Google
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
